Sona Nanotech Inc C.SONA

Alternate Symbol(s): SNANF

Technology Scientific & Technical Instruments

Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.

CSE:SONA - Post by User

Sona Nanotech Inc > Something to keep in mind

<< Previous

Bullboard Posts

Next >>

Comment by whatdoiknow123on Oct 23, 2020 3:57pm

153 Views

Post# 31772564

RE:RE:RE:Something to keep in mind

Moemoney42 wrote:

dart321 wrote: One more important point. When these health care systems reach their breaking point is when the death rate skyrockets up as we seen in Italy and NY. So if anyone from HC or the FDA reads this, GET THOSE ANTIGEN TEST APPROVED, all of them!!!!!!!!!!!!!!!!!

I think their focus is more on treatments lately as the spread is obviously too hard to contain, so better to focus on treatments..

Sorry Moemoney but that is incorrect. Treatments are for seriously ill patients,(unless you are Trump) and will have no relevance to the spread of the virus which is indeed starting to get out of control and things will, unfortunately, get much worse as we get into the winter season.

You yourself pointed out earlier how the Gilead SP rise was not very impressive and this is mainly because of the limited use of their drug due to clinical use necessity and cost. Your argument that Gilead´s unimpressive SP rise somehow reflected on the possibilities for Sona was pretty poor for you.

Testing (of all types) will be required on a massive scale and for much longer than most realise and testing is where the future emphasis and spending will be.

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (June 28, 2024)